0.2139
Can-Fite Biopharma Ltd ADR (CANF) Stock Split History
Can-Fite Biopharma Ltd ADR has split its stock 3 times since its initial public offering (IPO). The first stock split occurred on May 10, 2019 with the ratio of 1-for-15, meaning that for 15 shares of CANF owned pre-split, shareholders then owned 1 share. 2 more splits have been implemented since then. The most recent stock split took place on January 05, 2026 on a 1-for-20 basis.
These splits have increased CANF stock's liquidity and made it more appealing to a larger group of investors. However, it's important to remember that these actions only change the number of shares and the price per share with no impact on Can-Fite Biopharma Ltd ADR's total market capitalization.
For more detailed information of Can-Fite Biopharma Ltd ADR's stock splits, view the table below:
These splits have increased CANF stock's liquidity and made it more appealing to a larger group of investors. However, it's important to remember that these actions only change the number of shares and the price per share with no impact on Can-Fite Biopharma Ltd ADR's total market capitalization.
For more detailed information of Can-Fite Biopharma Ltd ADR's stock splits, view the table below:
CANF stock split list
| Date | Split Ratio |
|---|---|
| 2026-01-05 | 1 - for - 20 |
| 2023-01-09 | 1 - for - 10 |
| 2019-05-10 | 1 - for - 15 |
Will Can-Fite Biopharma Ltd ADR Stock Split in 2025?
The answer will depend on the decisions of the company's managers and market volatility. Can-Fite Biopharma Ltd ADR has not made an official announcement regarding whether it will enact a stock split or reverse stock split, but it has a history of doing so when CANF stock prices become too high or too low for retail investors. Therefore, the ultimate decisions will certainly be made by Can-Fite Biopharma Ltd ADR's board of directors. Typically, no action is taken until its price per share reaches a specific threshold.
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):